The aims of this study are three-folds: firstly to develop an assay that can accurately measure NT-proBNP 13-71aa levels in serum samples from patients with HF; secondly, to investigate whether frequent measurements of Gal-3 and or NT-proBNP concentrations following hospitalisation improves risk stratification; and finally to develop a Gal-3 and NT-proBNP driven stratification method (in addition to clinical predictors) to identify patients with HF at a higher risk of all-cause mortality and/or rehospitalisation. Here, NPPB is linked to hydrops fetalis.